Macitentan
Treatment for Pulmonary Arterial Hypertension
Typical Dosage: 10mg once daily
Effectiveness
85%
Safety Score
58%
Clinical Trials
20
Participants
6K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
10mg once daily
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$5,000
Side Effect Mgmt:$1,000
Total Annual:$126,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$180,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$331,579
Cost per Remission
$2,100,000
Macitentan Outcomes
for Pulmonary Arterial Hypertension
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+38%
Remission Rate
+6%
Common Side Effects
Anemia
+12%
Nasopharyngitis
+10%
Headache
+10%
Peripheral Edema
+8%
Sources:
Active Clinical Trials
2 active trials recruiting for Macitentan in Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945ACTIVE NOT RECRUITINGPHASE3
935 participants
INTERVENTIONAL
Phoenix, United States +273 more
Started: Jun 30, 2020
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
NCT05179876RECRUITINGPHASE3
280 participants
INTERVENTIONAL
Minsk, Belarus +42 more
Started: May 4, 2022
Completed Clinical Trials
12 completed trials for Macitentan in Pulmonary Arterial Hypertension
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
NCT00660179COMPLETEDPHASE3
742 participants
INTERVENTIONAL
Birmingham, United States +152 more
Started: May 1, 2008
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
NCT01841762COMPLETEDPHASE3
284 participants
INTERVENTIONAL
Birmingham, United States +80 more
Started: Apr 1, 2013
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
NCT05167825COMPLETEDPHASE3
7 participants
INTERVENTIONAL
Azumino-shi, Japan +10 more
Started: Nov 14, 2022
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
NCT02310672COMPLETEDPHASE4
89 participants
INTERVENTIONAL
Boston, United States +40 more
Started: Jun 1, 2015
OPsumit USers Registry
NCT02126943COMPLETED
2.69K participants
OBSERVATIONAL
Mobile, United States +145 more
Started: Apr 30, 2014
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
NCT00667823COMPLETEDPHASE3
550 participants
INTERVENTIONAL
Birmingham, United States +157 more
Started: Oct 17, 2008
Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
NCT02112487COMPLETEDPHASE3
88 participants
INTERVENTIONAL
Bron, France +31 more
Started: Jun 23, 2014
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
NCT03422328COMPLETEDPHASE3
151 participants
INTERVENTIONAL
Minsk, Belarus +33 more
Started: Apr 5, 2018
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
NCT02932410COMPLETEDPHASE3
165 participants
INTERVENTIONAL
Phoenix, United States +84 more
Started: Oct 24, 2017
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
NCT02558231COMPLETEDPHASE3
247 participants
INTERVENTIONAL
Phoenix, United States +57 more
Started: May 1, 2016
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
NCT01743001COMPLETEDPHASE3
226 participants
INTERVENTIONAL
Los Angeles, United States +54 more
Started: May 21, 2013
(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
NCT03362047COMPLETEDPHASE2
7 participants
INTERVENTIONAL
Cologne, Germany +2 more
Started: Mar 1, 2018
Showing 20 of 47 total trials